Business context and reporting period
Chemed Corporation filed this Form 10-K for the fiscal year ended December 31, 2011. Its two operating segments were VITAS, a hospice-care provider, and Roto-Rooter, a plumbing and drain-cleaning services business. The filing incorporates the audited financial statements and management’s discussion from the 2011 Annual Report; the supplied filing text does not include the underlying income statement or cash-flow figures, so full-year and fourth-quarter revenue, earnings, margins, and cash flow are not clear here.
Financial position and key metrics
- Debt: Long-term debt had a carrying value of $166.8 million and an estimated market value of $175.8 million at year-end. No variable-rate debt was outstanding at December 31, 2011. The company had a $350 million revolving credit facility.
- Liquidity: Cash, current assets, current liabilities, and available borrowing capacity are not clearly stated in the supplied text.
- VITAS revenue exposure: More than 90% of VITAS revenue came from Medicare and Medicaid; Medicaid accounted for 5% of VITAS revenue in 2011. Reimbursement is primarily per diem, leaving VITAS exposed to care-cost management and payment-rate changes.
- Medicare cap: In the fourth quarter, Chemed recorded a $2.6 million liability for three programs related to the first quarter of the 2012 Medicare cap measurement period. It also reversed $786,000, primarily associated with one program, for the 2011 cap measurement period, and reversed the remaining liability for its Phoenix program.
- Environmental liabilities: The recorded accrual for potential cleanup costs related to former subsidiary DuBois was $1.7 million. Chemed was contingently liable for up to an additional $14.9 million; management said payment of that additional amount was not probable and recorded no provision for it.
- Shareholder returns: Quarterly dividends per share were $0.14, $0.14, $0.16, and $0.16 in 2011. The board authorized an additional $100 million under the share repurchase program in November 2011.
Material changes versus the prior comparable period
The supplied text does not provide comparable 2010 and 2011 consolidated revenue, profit, cash flow, or margin figures, so year-over-year operating changes cannot be quantified. The filing reports an October 1, 2011 Medicare and Medicaid hospice base-rate increase of 2.5%. It also describes 2011 Medicare-cap adjustments, including the liability and reversals noted above.
Outlook, commentary, risks, and unusual items
- Outlook: No quantified earnings or revenue guidance is stated in the supplied text. Chemed says VITAS profitability depends substantially on controlling hospice-care costs, while payment increases may trail inflation. Roto-Rooter competes in fragmented, highly competitive local and regional markets.
- Regulatory and reimbursement exposure: VITAS is subject to Medicare and Medicaid payment rules, annual caps, claims audits, licensing and certification requirements, and other healthcare regulations. Changes in reimbursement, audit outcomes, or eligibility enforcement could affect revenue and profitability.
- Government investigations and litigation: The filing describes continuing government investigations and multiple qui tam complaints concerning alleged improper hospice admissions and billing. Chemed said it could not predict the outcome or estimate potential liability or loss. The filing also identifies employment-related class actions and a securities class action filed in January 2012; several potential losses could not be estimated.
- Other risks: The company cites debt and covenant constraints, interest-rate exposure, staffing and nurse shortages, competition, cybersecurity, and environmental cleanup liabilities. Management reported effective disclosure controls and no material change in internal control over financial reporting during the fourth quarter.
Important facts for investors to verify
- Review the incorporated 2011 Annual Report for consolidated and segment revenue, operating income, net income, cash flow, margins, cash balances, and full debt terms; those figures are not clear in the supplied filing text.
- Track VITAS Medicare-cap accruals, audit and recoupment developments, and the status and potential exposure of the government investigations and qui tam cases.
- Assess VITAS’s dependence on government reimbursement against wage, staffing, and other care-cost inflation.
- Confirm the amount of remaining borrowing capacity and compliance with credit-facility covenants.
- Monitor developments in the DuBois environmental matter and the pending litigation, for which some potential losses were not estimable.